The role of ezetimibe in LDL cholesterol goal attainment in very high risk patients: the rosuvastatin monotherapy looks to be insufficient

Laszlo MarkPandy Kalman Bekes County Hospital, 2nd Department of Medicine – Cardiology GyulaHungaryCorrespondence[email protected]

György ParaghMedical and Health Science Centre, University of Debrecen, 1st Department of Medicine DebrecenHungary

Istvan ReiberSt George Fejer County Hospital, 4th Department of Medicine SzekesfehervarHungary

"The role of ezetimibe in LDL cholesterol goal attainment in very high risk patients: the rosuvastatin monotherapy looks to be insufficient." Current Medical Research and Opinion, 27(10), pp. 1959–1960

Transparency

Declaration of funding

The authors declare no conflict of interest and have received no payment in preparation of this manuscript.

Declaration of financial/other relationships

The authors have previously received sponsorship from AstraZeneca, Hungary.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

The role of ezetimibe in LDL cholesterol goal attainment in very high risk patients: the rosuvastatin monotherapy looks to be insufficient

Declaration of funding

Declaration of financial/other relationships

Information for

Open access

Opportunities

Help and information

The role of ezetimibe in LDL cholesterol goal attainment in very high risk patients: the rosuvastatin monotherapy looks to be insufficient

Transparency

Declaration of funding

Declaration of financial/other relationships

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date

Your download is now in progress and you may close this window

Login or register to access this feature